NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company's proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. According to the company, NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses and is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge.
The company stated that the next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. NanoViricides noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale.
This development is significant because oral administration could improve patient compliance and reduce the burden on healthcare systems during outbreaks. The ability to treat Ebola with an oral medication would represent a major advancement, particularly in regions with limited infrastructure for intravenous therapies. The approval also demonstrates regulatory progress for NanoViricides' broad-spectrum antiviral platform, which has potential applications beyond Ebola, including mpox, COVID-19, and other viral infections.
The full press release is available at https://nnw.fm/1ewVT. For more information about NanoViricides, visit the company's website at https://www.nanoviricides.com.
